Richard J Daly
CIK 1635393 · President and CEO · last filed 2026-07-17
Richard J Daly is a President and CEO who has filed 54 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing shows the insider disposed of $8.5M of CPRX on Jul 17, 2026. Across all open-market trades the lifetime net is +$1.1M, making them a net buyer over the disclosed history. 5 SEC filings were submitted jointly with SYNERGY PHARMACEUTICALS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CPRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1500
CORAL GABLES, FL 33134
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | President and CEO | 0 | $31.49 | $0 | $989.8K | 32 | 2026-07-17 |
| OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Director | 0 | $20.65 | $0 | $25.0K | 7 | 2023-03-03 |
| PALISADE BIO, INC. (CUR) Delisted | Chief Executive Officer | 1,166 | — | — | $90.0K | 8 | 2017-11-09 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Director | — | — | — | $0 | 1 | 2017-06-30 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Director | — | — | — | $0 | 3 | 2016-06-29 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Disp (D) | −271,266 | -$8.54M | EDGAR |
| 2026-01-06 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +31,528 | $0 | EDGAR |
| 2025-12-30 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +810 | $0 | EDGAR |
| 2025-11-24 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +12,134 | $0 | EDGAR |
| 2025-08-28 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +27,030 | -$361.6K | EDGAR |
| 2025-08-26 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Notice (144) | −22,970 | -$473.6K | EDGAR |
| 2025-06-03 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Sell (S) | +70,000 | $1.74M | EDGAR |
| 2025-05-30 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Notice (144) | −70,000 | -$1.74M | EDGAR |
| 2025-02-19 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +2,426 | $0 | EDGAR |
| 2025-01-03 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Mixed | +31,505 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.